Page 3 - Rating Level News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rating level. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rating Level Today - Breaking & Trending Today

Empagliflozin does not decrease risk of hospitalization or death after myocardial infarction

1. In this randomized controlled trial, empagliflozin was not shown to decrease the risk of hospitalization for heart failure or death among patients after acute myocardial infarction (MI). 2. Safety outcomes were generally similar between the empagliflozin and placebo groups. Evidence Rating Level: 1 (Excellent) Study Rundown: It is well-established that sodium-glucose cotransporter 2 (SGLT2) ....

Minute Medicine Inc , Rating Level ,

Resistance training not superior to neuromuscular exercises for hip osteoarthritis

Resistance training not superior to neuromuscular exercises for hip osteoarthritis
2minutemedicine.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 2minutemedicine.com Daily Mail and Mail on Sunday newspapers.

Minute Medicine Inc , Rating Level , Hip Disability , Osteoarthritis Outcome Score ,

TG103 injections may be effective in achieving weight reduction in patients with obesity

1. In this randomized, double-blind, placebo-controlled trial, the use of once-weekly subcutaneous TG103 resulted in significant weight reduction at 12 weeks at all dosages. 2. It was deemed to be safe and effective, with pharmacokinetic findings in keeping with the weekly dose regimen recommended in preclinical studies. Evidence Rating Level: 1 (Excellent) Obesity, caused by ....

United States , Rating Level ,

Multivariate predictive model for bone marrow sampling in MGUS patients

1. A multivariate predictive model was developed to help determine when a bone marrow sample would help distinguish between patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). 2. The model aimed to minimize unnecessary bone marrow sampling in this population. Evidence Rating Level: 2 (Good) Study Rundown: MGUS may be ....

Minute Medicine Inc , Rating Level ,

Personalized therapy does not reduce hospitalization in chronic kidney disease

1. In this randomized controlled trial, algorithmic identification based on electronic health records (EHRs) and practice facilitators did not reduce hospitalization rates among patients with chronic kidney disease (CKD). 2. Among patients with an unknown ASCVD risk score, those deemed statin-eligible by the model were nearly twice as likely to have incident MACE. Evidence Rating ....

Minute Medicine Inc , Rating Level , Confidence Interval ,